Search research articles
Contact Us
Filters
Showing results (171-180 of 329) with videos related to
Page
of 33
Sort By:
The British Journal of Psychiatry : the Journal of Mental Science
|
October 2, 2024
Mortality associated with clozapine: what is the evidence?
Emilio Fernandez-Egea, Robert J Flanagan, David Taylor, et al.
Psychopharmacology
|
December 22, 2024
Working memory processes and the histamine-3 receptor in schizophrenia: a [<sup>11</sup>C]MK-8278 PET-fMRI study
Atheeshaan Arumuham, Ekaterina Shatalina, Matthew M Nour, et al.
Neuroscience and Biobehavioral Reviews
|
June 2, 2009
The dopaminergic basis of human behaviors: A review of molecular imaging studies
Alice Egerton, Mitul A Mehta, Andrew J Montgomery, et al.
Psychiatry Research
|
May 19, 2012
Limbic striatal dopamine D2/3 receptor availability is associated with non-planning impulsivity in healthy adults after exclusion of potential dissimulators
Suzanne J Reeves, Catherine Polling, Paul R A Stokes, et al.
Scientific Reports
|
November 5, 2017
Acute induction of anxiety in humans by delta-9-tetrahydrocannabinol related to amygdalar cannabinoid-1 (CB1) receptors
Sagnik Bhattacharyya, Alice Egerton, Euitae Kim, et al.
The International Journal of Neuropsychopharmacology
|
February 19, 2024
Histamine-3 Receptor Availability and Glutamate Levels in the Brain: A PET-1H-MRS Study of Patients With Schizophrenia and Healthy Controls
Atheeshaan Arumuham, Matthew M Nour, Mattia Veronese, et al.
Neuropsychopharmacology : Official Publication of the American College of Neuropsychopharmacology
|
November 19, 2016
Presynaptic Dopamine Capacity in Patients with Treatment-Resistant Schizophrenia Taking Clozapine: An [<sup>18</sup>F]DOPA PET Study
Euitae Kim, Oliver D Howes, Mattia Veronese, et al.
The Lancet. Psychiatry
|
March 21, 2020
Psychiatric symptoms caused by cannabis constituents: a systematic review and meta-analysis
Guy Hindley, Katherine Beck, Faith Borgan, et al.
Psychological Medicine
|
August 25, 2022
Reduced cortical cerebral blood flow in antipsychotic-free first-episode psychosis and relationship to treatment response
Pierluigi Selvaggi, Sameer Jauhar, Vasileia Kotoula, et al.
The Lancet. Psychiatry
|
December 21, 2019
Comparative effects of 18 antipsychotics on metabolic function in patients with schizophrenia, predictors of metabolic dysregulation, and association with psychopathology: a systematic review and network meta-analysis
Toby Pillinger, Robert A McCutcheon, Luke Vano, et al.
Page
of 33
Search research articles
Search
Showing results (171-180 of 329) with videos related to
Sort By:
Page
of 33
The British Journal of Psychiatry : the Journal of Mental Science
|
October 2, 2024
Mortality associated with clozapine: what is the evidence?
Emilio Fernandez-Egea, Robert J Flanagan, David Taylor, et al.
Psychopharmacology
|
December 22, 2024
Working memory processes and the histamine-3 receptor in schizophrenia: a [<sup>11</sup>C]MK-8278 PET-fMRI study
Atheeshaan Arumuham, Ekaterina Shatalina, Matthew M Nour, et al.
Neuroscience and Biobehavioral Reviews
|
June 2, 2009
The dopaminergic basis of human behaviors: A review of molecular imaging studies
Alice Egerton, Mitul A Mehta, Andrew J Montgomery, et al.
Psychiatry Research
|
May 19, 2012
Limbic striatal dopamine D2/3 receptor availability is associated with non-planning impulsivity in healthy adults after exclusion of potential dissimulators
Suzanne J Reeves, Catherine Polling, Paul R A Stokes, et al.
Scientific Reports
|
November 5, 2017
Acute induction of anxiety in humans by delta-9-tetrahydrocannabinol related to amygdalar cannabinoid-1 (CB1) receptors
Sagnik Bhattacharyya, Alice Egerton, Euitae Kim, et al.
The International Journal of Neuropsychopharmacology
|
February 19, 2024
Histamine-3 Receptor Availability and Glutamate Levels in the Brain: A PET-1H-MRS Study of Patients With Schizophrenia and Healthy Controls
Atheeshaan Arumuham, Matthew M Nour, Mattia Veronese, et al.
Neuropsychopharmacology : Official Publication of the American College of Neuropsychopharmacology
|
November 19, 2016
Presynaptic Dopamine Capacity in Patients with Treatment-Resistant Schizophrenia Taking Clozapine: An [<sup>18</sup>F]DOPA PET Study
Euitae Kim, Oliver D Howes, Mattia Veronese, et al.
The Lancet. Psychiatry
|
March 21, 2020
Psychiatric symptoms caused by cannabis constituents: a systematic review and meta-analysis
Guy Hindley, Katherine Beck, Faith Borgan, et al.
Psychological Medicine
|
August 25, 2022
Reduced cortical cerebral blood flow in antipsychotic-free first-episode psychosis and relationship to treatment response
Pierluigi Selvaggi, Sameer Jauhar, Vasileia Kotoula, et al.
The Lancet. Psychiatry
|
December 21, 2019
Comparative effects of 18 antipsychotics on metabolic function in patients with schizophrenia, predictors of metabolic dysregulation, and association with psychopathology: a systematic review and network meta-analysis
Toby Pillinger, Robert A McCutcheon, Luke Vano, et al.
Page
of 33